CN109219620B - 抗-tnfrsf25抗体 - Google Patents

抗-tnfrsf25抗体 Download PDF

Info

Publication number
CN109219620B
CN109219620B CN201780034593.5A CN201780034593A CN109219620B CN 109219620 B CN109219620 B CN 109219620B CN 201780034593 A CN201780034593 A CN 201780034593A CN 109219620 B CN109219620 B CN 109219620B
Authority
CN
China
Prior art keywords
leu
ala
gly
ser
pro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201780034593.5A
Other languages
English (en)
Chinese (zh)
Other versions
CN109219620A (zh
Inventor
T·H·施瑞博
J·T·哈特池恩斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pelican Therapeutics Inc
Original Assignee
Pelican Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pelican Therapeutics Inc filed Critical Pelican Therapeutics Inc
Publication of CN109219620A publication Critical patent/CN109219620A/zh
Application granted granted Critical
Publication of CN109219620B publication Critical patent/CN109219620B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Developmental Biology & Embryology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201780034593.5A 2016-06-09 2017-06-09 抗-tnfrsf25抗体 Expired - Fee Related CN109219620B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662348009P 2016-06-09 2016-06-09
US62/348,009 2016-06-09
PCT/US2017/036817 WO2017214547A1 (en) 2016-06-09 2017-06-09 Anti-tnfrsf25 antibodies

Publications (2)

Publication Number Publication Date
CN109219620A CN109219620A (zh) 2019-01-15
CN109219620B true CN109219620B (zh) 2023-01-31

Family

ID=59078259

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201780034593.5A Expired - Fee Related CN109219620B (zh) 2016-06-09 2017-06-09 抗-tnfrsf25抗体

Country Status (15)

Country Link
US (3) US10005843B2 (OSRAM)
EP (1) EP3468998B1 (OSRAM)
JP (1) JP6961625B2 (OSRAM)
KR (1) KR102423942B1 (OSRAM)
CN (1) CN109219620B (OSRAM)
AU (1) AU2017278192A1 (OSRAM)
BR (1) BR112018075222A2 (OSRAM)
CA (1) CA3026652A1 (OSRAM)
DK (1) DK3468998T3 (OSRAM)
IL (1) IL263406B2 (OSRAM)
MX (1) MX389320B (OSRAM)
RU (1) RU2746314C2 (OSRAM)
SG (1) SG11201810853UA (OSRAM)
WO (1) WO2017214547A1 (OSRAM)
ZA (1) ZA201808317B (OSRAM)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112014007426B1 (pt) 2011-09-30 2023-01-03 Teva Pharmaceuticals Australia Pty Ltd Anticorpos contra tl1a e seus usos
SG11201705844SA (en) * 2015-02-06 2017-08-30 Heat Biologics Inc Vector co-expressing vaccine and costimulatory molecules
TWI703158B (zh) 2015-09-18 2020-09-01 美商希佛隆公司 特異性結合tl1a之抗體
US12331320B2 (en) 2018-10-10 2025-06-17 The Research Foundation For The State University Of New York Genome edited cancer cell vaccines
EP4021494A1 (en) * 2019-08-30 2022-07-06 Pelican Therapeutics, Inc. Methods of treating cancer using tnfrsf25 antibodies
WO2021062371A1 (en) * 2019-09-26 2021-04-01 Pelican Therapeutics, Inc. Tnfrsf25-mediated treatments of immune diseases and disorders
WO2022212668A1 (en) * 2021-03-31 2022-10-06 Heat Biologics, Inc. Methods and compositions related to tnfrsf25/dr3 agonists
CN119256009A (zh) * 2022-06-17 2025-01-03 塞莱克辛有限公司 与人dr3特异性结合的抗体及其用途
CN120399074A (zh) * 2023-06-02 2025-08-01 安徽金百奥生物科技有限公司 一种与人dr3胞外域高亲和力的纳米抗体
GB202315963D0 (en) 2023-10-18 2023-11-29 Cancer Research Tech Ltd Binding molecules
US12319742B1 (en) * 2024-01-24 2025-06-03 Shattuck Labs, Inc. Antibodies that bind TNFRSF25

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101253199A (zh) * 2005-08-30 2008-08-27 迈阿密大学 免疫调节肿瘤坏死因子受体25(tnfr25)的激动剂、拮抗剂和免疫毒素
CN102770455A (zh) * 2009-08-03 2012-11-07 迈阿密大学 用于体内扩增调节性t细胞的方法
CN103592439A (zh) * 2013-09-03 2014-02-19 李翀 人尿路上皮癌特异性抗体及其应用
WO2016081455A1 (en) * 2014-11-17 2016-05-26 Pelican Therapeutics, Inc. Human tnfrsf25 antibody

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JPS61134325A (ja) 1984-12-04 1986-06-21 Teijin Ltd ハイブリツド抗体遺伝子の発現方法
US5618920A (en) 1985-11-01 1997-04-08 Xoma Corporation Modular assembly of antibody genes, antibodies prepared thereby and use
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
DK0531472T3 (da) 1991-03-06 2003-12-01 Merck Patent Gmbh Humaniserede monoklonale antistoffer
AU669124B2 (en) 1991-09-18 1996-05-30 Kyowa Hakko Kirin Co., Ltd. Process for producing humanized chimera antibody
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
GB9125979D0 (en) 1991-12-06 1992-02-05 Wellcome Found Antibody
ZA931148B (en) 1992-02-19 1993-08-18 Schering Corp Cloning and expression of humanized monoclonal antibodies against human interfluekin-4.
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
US5705154A (en) 1995-03-08 1998-01-06 Schering Corporation Humanized monoclonal antibodies against human interleukin-4
CA2536086C (en) 2003-08-20 2013-03-19 University Of Miami Inhibition of dr3 in the treatment of allergic lung inflammation
US7612179B2 (en) 2003-11-28 2009-11-03 Astrazeneca Ab antibodies binding to a C-terminal fragment of apoliopoprotein E
SG178712A1 (en) 2006-10-02 2012-03-29 Medarex Inc Human antibodies that bind cxcr4 and uses thereof
FR2907341B1 (fr) 2006-10-18 2012-08-17 Pf Medicament Utilisation d'un anticorps anti-cd151 pour le traitement du cancer
WO2010033913A1 (en) 2008-09-22 2010-03-25 Icb International, Inc. Antibodies, analogs and uses thereof
WO2011106707A2 (en) * 2010-02-26 2011-09-01 Human Genome Sciences, Inc. Antibodies that specifically bind to dr3
GB201020995D0 (en) 2010-12-10 2011-01-26 Bioinvent Int Ab Biological materials and uses thereof
JP2013040160A (ja) 2011-07-01 2013-02-28 Genentech Inc 自己免疫疾患を治療するための抗ｃｄ８３アゴニスト抗体の使用
US20140193410A1 (en) 2013-01-09 2014-07-10 University Of Miami Compositions and Methods for the Regulation of T Regulatory Cells Using TL1A-Ig Fusion Protein
RU2551235C2 (ru) * 2013-08-26 2015-05-20 Илья Владимирович Духовлинов Гуманизированное моноклональное антитело, специфичное к синдекану-1

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101253199A (zh) * 2005-08-30 2008-08-27 迈阿密大学 免疫调节肿瘤坏死因子受体25(tnfr25)的激动剂、拮抗剂和免疫毒素
CN102770455A (zh) * 2009-08-03 2012-11-07 迈阿密大学 用于体内扩增调节性t细胞的方法
CN103592439A (zh) * 2013-09-03 2014-02-19 李翀 人尿路上皮癌特异性抗体及其应用
WO2016081455A1 (en) * 2014-11-17 2016-05-26 Pelican Therapeutics, Inc. Human tnfrsf25 antibody

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
A series of Fas receptor agonist antibodies that demonstrate an inverse correlation between affinity and potency;M Chodorge,et al;《Cell Death Differ.》;20120120;第19卷(第7期);第1187-1195页 *
Livin与胱天蛋白酶-3在中耳胆脂瘤中的表达及临床意义;李树华等;《华西医学》;20150612;第30卷(第6期);第1083-1086页 *

Also Published As

Publication number Publication date
RU2746314C2 (ru) 2021-04-12
IL263406B1 (en) 2023-05-01
RU2018143977A (ru) 2020-07-09
WO2017214547A1 (en) 2017-12-14
DK3468998T3 (en) 2022-03-07
KR20190015716A (ko) 2019-02-14
US20210017287A1 (en) 2021-01-21
MX389320B (es) 2025-03-20
JP6961625B2 (ja) 2021-11-10
US10683359B2 (en) 2020-06-16
MX2018014716A (es) 2019-03-11
AU2017278192A1 (en) 2018-12-13
RU2018143977A3 (OSRAM) 2020-10-05
KR102423942B1 (ko) 2022-07-22
IL263406A (en) 2018-12-31
CA3026652A1 (en) 2017-12-14
IL263406B2 (en) 2023-09-01
EP3468998B1 (en) 2021-12-01
US20180312599A1 (en) 2018-11-01
SG11201810853UA (en) 2019-01-30
EP3468998A1 (en) 2019-04-17
JP2019526528A (ja) 2019-09-19
ZA201808317B (en) 2019-08-28
CN109219620A (zh) 2019-01-15
US20170355773A1 (en) 2017-12-14
BR112018075222A2 (pt) 2019-03-19
US10005843B2 (en) 2018-06-26

Similar Documents

Publication Publication Date Title
CN109219620B (zh) 抗-tnfrsf25抗体
US20240400688A1 (en) Enhanced depletion of targeted cells with cd47 blockade and an immune costimulatory agonist
JP6907124B2 (ja) Ｃｄｈ３及びｃｄ３に対する二重特異性抗体構築物
US10683358B2 (en) Human TNFRSF25 antibody
CN109485729A (zh) Bcma和cd3的结合分子
JP2018503399A (ja) 多特異性免疫調節抗原結合構築物
KR20160077155A (ko) 인간 암을 치료하기 위한 특이적 항-ｃｄ38 항체
KR102608028B1 (ko) 인간 원형질막 소포 관련 단백질 pv-1에 특이적으로 결합하는 단일클론항체 및 이의 제조방법과 용도
WO2021217893A1 (zh) 结合tigit抗原的抗体及其制备方法与应用
CA3114955A1 (en) Combination therapy for cancer
JP2024514246A (ja) Ｃｌｄｎ１８．２抗原結合タンパク質およびその使用
CN114790241B (zh) 抗tigit抗体及其应用
CN116710486A (zh) 用于治疗癌症的多特异性抗体
AU2021232041A9 (en) Anti-GITR antibodies and uses thereof
CN116554325A (zh) 抗b7h3抗体及其应用
KR20230159823A (ko) Cd112r에 대한 항체 및 이의 용도
HK40007009B (en) Anti-tnfrsf25 antibodies
TWI902626B (zh) 嵌合抗原及t細胞受體以及使用方法
HK1257824B (en) Enhanced depletion of targeted cells with cd47 blockade and an immune costimulatory agonist

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20230131